The advances in genomics, proteomics, and bioinformatics have directed the development of new anticancer agents to reduce drug abuse and increase safe and specific drug treatment. Theranostics, combining therapy and diagnosis, is an appealing approach for chemotherapy in medicine which exhibits improved biodistribution, selective cancer targeting ability, reduced toxicity, masked drug efficacy, and minimum side effects. The role of diagnosis tools in theranostics is to collect the information of the diseased state before and after specific treatment. Magnetic particle-, mesoporous silica-, various carbon allotrope-, and polymer nanoparticle-based theranostic systems are well accepted and clinically significant. Currently, small conjugate-based systems have received much attention for cancer treatment and diagnosis. The structural architecture of these systems is relatively simple, compact, biocompatible, and unidirectional. In this tutorial review, we summarize the latest developments on small conjugate based theranostic agents for tumor treatment and diagnosis using fluorescence and magnetic resonance imaging (MRI).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/c5cs00224a | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Self-Assembled PEGylated Nanocubes Based on Hydrophobic Camptothecin and Doxorubicin for Combinational Therapy of Colorectal Cancer.
ACS Appl Mater Interfaces
October 2024
Department of Bioengineering, School of Life Sciences, Zhengzhou University, 100# Science Avenue, Zhengzhou 450001, PR China.
Article Synopsis
- Researchers created a dual-hydrophobic drug conjugate, CPT-ss-DOX, which self-assembles into nanocubes for targeted colorectal cancer treatment.
- These PEGylated nanocubes improve the solubility, stability, and retention of the drugs, allowing for better accumulation at tumor sites and enhanced cancer cell toxicity compared to traditional drug mixtures.
- The study shows that these nanocubes not only inhibit tumor growth more effectively but also reduce cardiac toxicity, highlighting their potential for clinical use in cancer therapy.
Antibody nanoparticle conjugate-based targeted immunotherapy for non-small cell lung cancer.
Sci Adv
June 2024
Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Article Synopsis
- Immune checkpoint inhibitors are changing how non-small cell lung cancer is treated, but they still have low effectiveness.
- A new approach called antibody-conjugated drug-loaded nanotherapeutics (ADN) combines immunotherapy with targeted therapy for better results.
- In tests, a specific ADN combining anti-CD47 and anti-PDL1 antibodies with a drug targeting the PI3K/AKT/mTOR pathway showed improved tumor-killing capabilities in mice compared to existing treatments.
Amphiphilic α-Peptoid-deoxynojirimycin Conjugate-based Multivalent Glycosidase Inhibitor for Hypoglycemic Effect and Fluorescence Imaging.
J Med Chem
April 2024
College of Chemistry and Materials Science, State Key Laboratory of New Pharmaceutical Preparations and Excipients, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis (Ministry of Education), Key Laboratory of Chemical Biology of Hebei Province, Hebei Research Center of the Basic Discipline of Synthetic Chemistry, Hebei University, Baoding 071002, P. R. China.
Article Synopsis
- - Researchers are developing multivalent glycosidase inhibitors derived from 1-deoxynojirimycin to target α-glucosidases, but the effectiveness of self-assembly in living systems still needs more investigation.
- - They created two amphiphilic compounds and examined their ability to self-assemble, inhibit α-glucosidases, and provide fluorescence imaging in living organs.
- - One compound showed better inhibition and successfully formed a complex that could be visualized in the small intestine, suggesting that this self-assembly strategy could lead to new hypoglycemic drug designs.
RNA interference in the era of nucleic acid therapeutics.
Nat Biotechnol
March 2024
Research & Development, Alnylam Pharmaceuticals, Cambridge, MA, USA.
Two decades of research on RNA interference (RNAi) have transformed a breakthrough discovery in biology into a robust platform for a new class of medicines that modulate mRNA expression. Here we provide an overview of the trajectory of small-interfering RNA (siRNA) drug development, including the first approval in 2018 of a liver-targeted siRNA interference (RNAi) therapeutic in lipid nanoparticles and subsequent approvals of five more RNAi drugs, which used metabolically stable siRNAs combined with N-acetylgalactosamine ligands for conjugate-based liver delivery. We also consider the remaining challenges in the field, such as delivery to muscle, brain and other extrahepatic organs.
View Article and Find Full Text PDFCooperatively designed aptamer-PROTACs for spatioselective degradation of nucleocytoplasmic shuttling protein for enhanced combinational therapy.
Chem Sci
December 2023
State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University Nanjing 210023 China
Nucleocytoplasmic shuttling proteins (NSPs) have emerged as a promising class of therapeutic targets for many diseases. However, most NSPs-based therapies largely rely on small-molecule inhibitors with limited efficacy and off-target effects. Inspired by proteolysis targeting chimera (PROTAC) technology, we report a new archetype of PROTAC (PS-ApTCs) by introducing a phosphorothioate-modified aptamer to a CRBN ligand, realizing tumor-targeting and spatioselective degradation of NSPs with improved efficacy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!